Literature DB >> 9345537

Functional MRI and the study of OCD: from symptom provocation to cognitive-behavioral probes of cortico-striatal systems and the amygdala.

H C Breiter1, S L Rauch.   

Abstract

Functional magnetic resonance imaging (fMRI) first appeared in 1991. Since that time there has been a burgeoning use of the technology by psychiatric researchers and neuroscientists. Our group first used fMRI to study obessive compulsive disorder (OCD) with a symptom provocation paradigm and then moved to the use of circuitry-specific cognitive-behavioral probes. The techniques we utilized for the symptom provocation study remain valid today, but have been supplemented by a wide array of new tools. Functional MRI continues to be a rapidly developing technology which could become the gold standard for neuroimaging research in psychiatry. With this in mind, this paper focuses on the past, present, and future applications of fMRI to one model illness, namely OCD. We examine the strengths and limitations of our initial OCD symptom provocation study and then evaluate the use of fMRI with cognitive-behavioral probes of cortico-striatal circuitry and limbic (amygdala) circuitry. We conclude with a brief summary of foreseeable developments which will influence the implementation of fMRI for psychiatric neuroscience in general.

Entities:  

Mesh:

Year:  1996        PMID: 9345537     DOI: 10.1006/nimg.1996.0063

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  30 in total

1.  A preliminary study of the neural correlates of the intensities of self-reported gambling urges and emotions in men with pathological gambling.

Authors:  Iris M Balodis; Cheryl M Lacadie; Marc N Potenza
Journal:  J Gambl Stud       Date:  2012-09

2.  Lateral orbitofrontal dysfunction in the Sapap3 knockout mouse model of obsessive–compulsive disorder

Authors:  Huimeng Lei; Juan Lai; Xiaohong Sun; Qunyuan Xu; Guoping Feng
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

Review 3.  Pediatric indications for deep brain stimulation.

Authors:  Matthew F DiFrancesco; Casey H Halpern; Howard H Hurtig; Gordon H Baltuch; Gregory G Heuer
Journal:  Childs Nerv Syst       Date:  2012-07-25       Impact factor: 1.475

4.  Independent component analysis of resting state activity in pediatric obsessive-compulsive disorder.

Authors:  Patricia Gruner; An Vo; Miklos Argyelan; Toshikazu Ikuta; Andrew J Degnan; Majnu John; Bart D Peters; Anil K Malhotra; Aziz M Uluğ; Philip R Szeszko
Journal:  Hum Brain Mapp       Date:  2014-05-28       Impact factor: 5.038

5.  Specialized pathways from the primate amygdala to posterior orbitofrontal cortex.

Authors:  Clare Timbie; Helen Barbas
Journal:  J Neurosci       Date:  2014-06-11       Impact factor: 6.167

6.  Neuropsychological disposition and its impact on the executive functions and cognitive style in patients with obsessive-compulsive disorder.

Authors:  Sreemoyee Tarafder; Pallabi Bhattacharya; Debika Paul; Gautam Bandyopadhyay; Pritha Mukhopadhyay
Journal:  Indian J Psychiatry       Date:  2006-04       Impact factor: 1.759

7.  Unconditioned stimulus pathways to the amygdala: effects of lesions of the posterior intralaminar thalamus on foot-shock-induced c-Fos expression in the subdivisions of the lateral amygdala.

Authors:  E Lanuza; J Moncho-Bogani; J E Ledoux
Journal:  Neuroscience       Date:  2008-06-19       Impact factor: 3.590

8.  Task-related dissociation in ERN amplitude as a function of obsessive-compulsive symptoms.

Authors:  Theo O J Gründler; James F Cavanagh; Christina M Figueroa; Michael J Frank; John J B Allen
Journal:  Neuropsychologia       Date:  2009-03-17       Impact factor: 3.139

9.  Disconnection syndromes of basal ganglia, thalamus, and cerebrocerebellar systems.

Authors:  Jeremy D Schmahmann; Deepak N Pandya
Journal:  Cortex       Date:  2008-05-23       Impact factor: 4.027

Review 10.  Disrupting disordered neurocircuitry: treating refractory psychiatric illness with neuromodulation.

Authors:  Susannah J Tye; Mark A Frye; Kendall H Lee
Journal:  Mayo Clin Proc       Date:  2009-06       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.